161 In the index

Thymosin alpha-1 TA1

A thymus-derived peptide approved in some countries (as Zadaxin) for chronic hepatitis and used alongside certain cancer treatments to help the immune system. Human studies in those markets support immune benefits for these specific conditions, though it isn't FDA-approved in the U.S.

Also known as Thymalfasin, Zadaxin, Thymosin alpha 1, Thymosin alpha1, alpha1-Thymosin, Thymosin alpha1 (human), thymalfasine, timalfasina

Effects Heal Immune

Routes Subcutaneous

Legal status Prescription drug

WADA Not listed

Molecular Structure of C₁₂₉H₂₁₅N₃₃O₅₅

Drag to rotate · scroll to zoom

PubChem has no 3D conformer for this molecule, so this is the flat structure.

Chemistry

Formula: C129H215N33O55
Molar mass: 3108.3
CAS: 62304-98-7
PubChem CID: 16130571
IUPAC name: (4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S,3R)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]-6-aminohexanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-6-aminohexanoyl]amino]-4-carboxybutanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]propanoyl]amino]-5-[[(1S)-3-amino-1-carboxy-3-oxopropyl]amino]-5-oxopentanoic acid
InChIKey: NZVYCXVTEHPMHE-ZSUJOUNUSA-N

Reported dosing

Approved label

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 1.6 mg, twice weekly

Reported range 0.9-1.6 mg, twice weekly

Route Subcutaneous injection

Frequency Twice weekly

Duration Weeks to months, per approved international protocols

Approved in some countries (as Zadaxin) for chronic hepatitis and as an adjunct to certain cancer treatments; not FDA-approved in the US.

Where this comes from International prescribing information

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.

Variants

Name	Abbr	Route	Notes
Thymalfasin	TA1-P	Subcutaneous	The pharmaceutical-grade prescribed form.